- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.10.24 | Molecure inks $32 million deal with Ocean Biomedical for cancer therapy | 2 | Investing.com | ||
| 15.10.24 | Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. | 193 | GlobeNewswire (Europe) | This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as... ► Artikel lesen | |
| MOLECURE Aktie jetzt für 0€ handeln | |||||
| 31.07.24 | Avicenna Biosciences, Inc.: Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs | 388 | Business Wire | Molecure S.A. ('Molecure', SWE Ticker: MOC) and Avicenna Biosciences, Inc. announced today that they have entered into a strategic research collaboration to facilitate the discovery and development... ► Artikel lesen | |
| 21.05.24 | Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatment of pulmonary sarcoidosis in selected countries of the European Union and Norway | 194 | GlobeNewswire (Europe) | OATD-01 is a first-in-class chitotriosidase 1 (CHIT1) inhibitor with the potential to modify the course of disease in sarcoidosis and other interstitial lung diseases.Obtaining regulatory approvals... ► Artikel lesen | |
| 03.04.24 | Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025 | 218 | GlobeNewswire (Europe) | Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare... ► Artikel lesen | |
| 22.03.24 | Molecure: First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis | 145 | GlobeNewswire (Europe) | - OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 1,155 | -1,89 % | Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts | ||
| IMMATICS | 5,260 | +1,45 % | Bristol Myers Squibb und der große Hoffnungsträger - Immatics-Deal vor dem Aus | Vor knapp einem Jahr sorgte Bristol Myers Squibb mit einem Übernahme-Doppelschlag für Furore. Um Weihnachten herum kündigten die Amerikaner die Akquisitionen von Karuna Therapeutics und RayzeBio an.... ► Artikel lesen | |
| ALDEYRA | 5,222 | +0,54 % | Aldeyra Therapeutics Aktie: Umsatzprognosen klar übertroffen! | Die Aldeyra Therapeutics Aktie verzeichnete am 23. November einen bemerkenswerten Handelstag mit einem Kursanstieg von 1,73 Prozent auf 4,70 EUR. Der Biotech-Konzern, der sich auf die Entwicklung von... ► Artikel lesen | |
| MEDIFAST | 15,380 | +1,45 % | Medifast Aktie: Was heißt das jetzt konkret? | Die Medifast Aktie verzeichnete am 29. Oktober 2024 einen bescheidenen Kursanstieg von 2,47% auf 17,84 USD. Dieser leichte Aufschwung setzte sich am Folgetag fort, mit einem weiteren Plus von 3,81%... ► Artikel lesen | |
| PHARMING | 0,864 | -0,17 % | PHARMING TECHNOLOGIES B V: Pharming Technologies B.V. has received the necessary regulatory approval for the recommended cash offer to the shareholders of Abliva AB (publ) | ||
| COHERUS | 1,325 | +1,77 % | Coherus BioSciences, Inc.: Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 | - Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate - - Antitumor... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 11,400 | -6,56 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody | Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy... ► Artikel lesen | |
| INNOVIVA | 18,200 | 0,00 % | Basilea Pharmaceutica AG: Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera (ceftobiprole) in the United States | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, December 16, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 2,200 | 0,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update | Conference call planned for later in Q4 2024 to provide updates on NurOwn® program
NEW YORK, Nov. 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.... ► Artikel lesen | |
| ARMATA PHARMACEUTICALS | 1,970 | 0,00 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa ... | Results demonstrate that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile
LOS... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,145 | 0,00 % | SIGA Technologies Inc.: TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses | Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno Pharma Co., Ltd. engaged as exclusive distributor... ► Artikel lesen | |
| DBV TECHNOLOGIES | 0,804 | -0,99 % | DBV Technologies S.A.: Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF | AMF Regulated InformationChâtillon, France, January 13, 2025
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies (Euronext: DBV - ISIN: FR0010417345... ► Artikel lesen | |
| LIQUIDIA | 13,580 | -1,59 % | Liquidia Corp's Geschäftsführer verkauft Aktien im Wert von 6.319 US-Dollar | ||
| MATINAS BIOPHARMA | 0,581 | 0,00 % | Matinas BioPharma Holdings, Inc. - 8-K, Current Report | ||
| SYNDAX PHARMACEUTICALS | 13,700 | 0,00 % | Incyte And Syndax: FDA Approves Niktimvo 9 Mg And 22 Mg Vial Sizes | WASHINGTON (dpa-AFX) - Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that the U.S. Food and Drug Administration has approved Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes.... ► Artikel lesen |
MOLECURE SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,135 (-5,56 %) liegt der Kurs bei 2,295 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOLECURE SA finden Sie auf Wallstreet Online.
